KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Return on Equity (2016 - 2025)

Travere Therapeutics' Return on Equity history spans 14 years, with the latest figure at 0.26% for Q4 2025.

  • For Q4 2025, Return on Equity rose 33.0% year-over-year to 0.26%; the TTM value through Dec 2025 reached 0.26%, up 33.0%, while the annual FY2025 figure was 0.28%, 29.0% up from the prior year.
  • Return on Equity reached 0.26% in Q4 2025 per TVTX's latest filing, up from 0.0% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 5.32% in Q2 2024 to a low of 0.78% in Q3 2021.
  • Average Return on Equity over 5 years is 0.36%, with a median of 0.0% recorded in 2025.
  • Peak YoY movement for Return on Equity: surged 493bps in 2024, then plummeted -533bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.71% in 2021, then surged by 204bps to 0.74% in 2022, then soared by 49bps to 1.1% in 2023, then plummeted by -106bps to 0.06% in 2024, then surged by 510bps to 0.26% in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Return on Equity are 0.26% (Q4 2025), 0.0% (Q3 2025), and 0.0% (Q2 2025).